Cargando…

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis

BACKGROUND: Expanding antiviral therapy to benefit more populations and optimizing treatment to improve prognoses are two main objectives in current guidelines on antiviral therapy. However, the guidelines do not recommend antiviral therapy for inactive hepatitis B surface antigen (HBsAg) carriers (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Aixin, Lin, Xiao, Lu, Junfeng, Ren, Shan, Cao, Zhenhuan, Zheng, Sujun, Hu, Zhongjie, Li, Hong, Shen, Chengli, Chen, Xinyue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600041/ https://www.ncbi.nlm.nih.gov/pubmed/34804072 http://dx.doi.org/10.3389/fimmu.2021.779347

Ejemplares similares

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance
por: Lin, Xiao, et al.
Publicado: (2022)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a
por: Yang, Yanlin, et al.
Publicado: (2018)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
por: Zhao, Jing, et al.
Publicado: (2023)

AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS
por: Chaudhury, S., et al.
Publicado: (1993)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
por: Roade, Luisa, et al.
Publicado: (2023)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure
por: Chen, Qing, et al.
Publicado: (2019)

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
por: Al Ashgar, Hamad, et al.
Publicado: (2017)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Low serum hyaluronic acid levels associated with spontaneous HBsAg clearance
por: Harkisoen, S., et al.
Publicado: (2015)

Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors
por: Ie, Susan I, et al.
Publicado: (2010)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
por: Wang, Peipei, et al.
Publicado: (2023)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers
por: Li, Hong, et al.
Publicado: (2022)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Prevalence of hepatitis delta antibody among HBsAg carriers in Saudi Arabia
por: Al Traif, Ibrahim, et al.
Publicado: (2004)

Phylogenetic analysis and prevalence of Delta hepatitis among HBsAg carriers in Afghanistan
por: Husseini, Abbas Ali, et al.
Publicado: (2022)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection
por: Nam, Soon Woo, et al.
Publicado: (2007)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen
por: Park, Joonhong, et al.
Publicado: (2021)

Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups
por: Ning, Jing, et al.
Publicado: (2022)

HBsAg seroprevalence among Senegalese militaries
por: Ndiaye, Abdoul A, et al.
Publicado: (2015)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
por: Lee, Jaehyeon, et al.
Publicado: (2023)

A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers
por: Wang, Yuting, et al.
Publicado: (2021)

Low prevalence of hepatitis delta infection in Cuban HBsAg carriers: Prospect for elimination
por: de los Ángeles Rodríguez Lay, Licel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i7fc4ivsjgib959jsbdgm3jfb3